Please login to the form below

Not currently logged in
Email:
Password:

Merrimack Pharma

This page shows the latest Merrimack Pharma news and features for those working in and with pharma, biotech and healthcare.

Ipsen buys cancer business from stripped down Merrimack

Ipsen buys cancer business from stripped down Merrimack

Ipsen buys cancer business from stripped down Merrimack. Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval. ... French drugmaker Ipsen will pay $575m to buy Merrimack Pharma's oncology business, headed by

Latest news

  • Daiichi pulls study of patritumab in lung cancer Daiichi pulls study of patritumab in lung cancer

    Other companies working on HER3 inhibitors include Merrimack Pharma, whose seribantumab (MM-121) candidate is in phase III, as well as GlaxoSmithKline with GKS2849330 (phase I) and Roche's Genentech unit ... The antibody was developed by Daiichi Sankyo's

  • Baxter and Merrimack file pancreatic cancer drug in EU Baxter and Merrimack file pancreatic cancer drug in EU

    Baxter and Merrimack file pancreatic cancer drug in EU. MM-398 is thought to help direct the active drug into tumours. ... Baxter and Merrimack Pharma have filed for approval of their pancreatic cancer therapy MM-398 in the EU, a few days after the FDA

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics